0.34
+0(+0.00%)
Currency In USD
| Previous Close | 0.34 |
| Open | 0.32 |
| Day High | 0.36 |
| Day Low | 0.32 |
| 52-Week High | 1.73 |
| 52-Week Low | 0.29 |
| Volume | 494,149 |
| Average Volume | 609,930 |
| Market Cap | 6,075 |
| PE | -0.13 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.73 |
| Moving Average 200 Days | 1.02 |
| Change | 0 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $0.9 as of December 04, 2025 at a share price of $0.34. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $9.26 as of December 04, 2025 at a share price of $0.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
GlobeNewswire Inc.
8 hours ago
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the
Akari Therapeutics Announces Release of the Next CEO Corner Segment
GlobeNewswire Inc.
Nov 25, 2025 2:00 PM GMT
Access the Akari CEO Corner here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
GlobeNewswire Inc.
Nov 18, 2025 1:35 PM GMT
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from preclinical to clinical milestonesTAMPA and LONDON, Nov